Effect of Heat on Melphalan in Mice
Author Information
Author(s): D.J. Honess, J. Donaldson, P. Workman, N.M. Bleehen
Primary Institution: MRC Unit and University Department of Clinical Oncology and Radiotherapeutics
Hypothesis
Does systemic hyperthermia at 41°C affect the pharmacokinetics of melphalan in mice?
Conclusion
Systemic heat at 41°C increases plasma and tumour concentrations of melphalan, but does not explain the therapeutic gain observed with this combination.
Supporting Evidence
- Heating increased melphalan concentrations in plasma and tumors.
- Plasma concentrations were 2.5-4 times higher in heated animals.
- Tumor/plasma ratios were generally lower in heated animals.
- Elimination half-life of melphalan was longer in heated animals.
- Area under the curve (AUC) for melphalan was increased by 1.2-1.5 in heated animals.
Takeaway
Heating mice makes the medicine melphalan work better in their tumors, but it doesn't explain why it works better than just using the medicine alone.
Methodology
C3H mice were heated at 41°C for 45 minutes, then given melphalan, and drug concentrations were measured in plasma and tumors using HPLC.
Limitations
The study only measured average drug concentrations in homogenized tumors, lacking information on intracellular and extracellular concentrations.
Participant Demographics
Female C3H/He and C3H/Km mice, weighing 20-30 g.
Statistical Information
P-Value
p<0.005
Confidence Interval
95% confidence limits
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website